Frank Mottola
CIK: 0001804567
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SUPERNUS PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (55 total)
- Oct 30, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
100K shares- - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct1.7K shares- - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct797 shares at avg. $46.57$37K - Jul 29, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
1.7K shares- - Mar 9, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct1.6K shares at avg. $53.65$87K - Mar 6, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct1.8K shares at avg. $54.73$98K - Mar 6, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct3.8K shares- - Feb 28, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
3.8K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct977 shares at avg. $50.69$50K - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.9K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.9K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct750 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct603 shares at avg. $51.35$31K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.1K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct670 shares at avg. $50.86$34K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
750 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.3K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.3K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct368 shares at avg. $50.86$19K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.1K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectEmployee Stock Option (Right to Buy)
13.5K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
3K shares- - Dec 19, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct15K shares at avg. $25.30$380K - Dec 19, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct15K shares at avg. $50.47$757K - Dec 19, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct5K shares at avg. $50.22$251K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 100,000 | - | - | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 1,650 | - | $0 | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 797 | $46.57 | $37,116 | Direct |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 1,650 | - | - | Direct |
| Mar 9, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 1,623 | $53.65 | $87,074 | Direct |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 1,793 | $54.73 | $98,131 | Direct |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 3,750 | - | $0 | Direct |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 3,750 | - | - | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 977 | $50.69 | $49,524 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,875 | - | $0 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,875 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 750 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 603 | $51.35 | $30,964 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,125 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 670 | $50.86 | $34,076 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 750 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,250 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,250 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 368 | $50.86 | $18,716 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,125 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Employee Stock Option (Right to Buy) | 13,500 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 3,000 | - | - | Direct |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 15,000 | $25.30 | $379,500 | Direct |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 15,000 | $50.47 | $757,050 | Direct |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 5,000 | $50.22 | $251,100 | Direct |
1-25 of 55 transactions
About Mottola Frank
Mottola Frank (SEC CIK 0001804567) files insider reports with the SEC as SVP, Chief Tech. Ops. Officer of SUPERNUS PHARMACEUTICALS, INC. (SUPN).
Signal8 holds 20 ownership filings by Mottola Frank, all Form 4s, filed between Nov 8, 2024 and Nov 2, 2026. Those filings report 55 transactions, from Nov 7, 2024 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mottola Frank's filings is in ROCKVILLE, MD.
Recent filings by Mottola Frank
- Oct 30, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Aug 12, 2026: Option exercise of SUPN shares (Form 4, code M).
- Aug 12, 2026: Tax withholding of SUPN shares (Form 4, code F).
- Jul 29, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Mar 9, 2026: Open-market sale of SUPN shares (Form 4, code S).
Other insiders filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Khattar Jack A., President, CEO
- Rubin Jonathan, SVP, Chief Medical Officer
- DEC TIMOTHY C, Senior Vice-President & CFO
- Horich William Todd, SVP, Commercial Operations
- Bhatt Padmanabh P., Sr. VP of IP, CSO
- Hudson Frederick M., Director